Strassel Catherine, Gachet Christian, Lanza François
Université de Strasbourg, Inserm, EFS Grand Est, BPPS UMR-S 1255, FMTS, 67000 Strasbourg, France.
Université de Strasbourg, Inserm, EFS Grand Est, BPPS UMR-S 1255, FMTS, 67000 Strasbourg, France.
Transfus Clin Biol. 2018 Sep;25(3):220-227. doi: 10.1016/j.tracli.2018.07.005. Epub 2018 Aug 25.
The severely decreased platelet counts (10-30.10 platelets/μL) frequently observed in patients undergoing chemotherapy, radiation treatment or organ transplantation are associated with life-threatening increased bleeding risks. To circumvent these risks, platelet transfusion remains the treatment of choice, despite some limitations which include a limited shelf-life, storage-related deterioration, the development of alloantibodies in recipients and the transmission of infectious diseases. A sustained demand has evolved in recent years for controlled blood products, free of infectious, inflammatory and immune risks. As a consequence, the challenge for blood centers in the near future will be to ensure an adequate supply of blood platelets, which calls for a reassessment of our transfusion models. To meet this challenge, many laboratories are now turning their research efforts towards the in vitro and customized production of blood platelets.
在接受化疗、放疗或器官移植的患者中经常观察到血小板计数严重下降（10 - 30×10⁹血小板/μL），这与危及生命的出血风险增加有关。为规避这些风险，尽管存在一些局限性，包括保质期有限、储存相关的变质、受者中同种抗体的产生以及传染病的传播，但血小板输注仍然是首选治疗方法。近年来，对无感染、炎症和免疫风险的可控血液制品的需求持续增长。因此，血液中心在不久的将来面临的挑战将是确保血小板的充足供应，这需要重新评估我们的输血模式。为应对这一挑战，许多实验室现在正将研究工作转向血小板的体外定制生产。
